Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes

<p>The treatment of diabetes has been mainly focused on maintaining normal blood glucose concentrations. Insulin and hypoglycemic agents have been used as standard therapeutic strategies. However, these are characterized by limited efficacy and adverse side effects, making the development of n...

Full description

Bibliographic Details
Main Author:	Francisco Castaneda, Antje Burse, Wilhelm Boland, Rolf K-H. Kinne
Format:	Article
Language:	English
Published:	Ivyspring International Publisher 2007-01-01
Series:	International Journal of Medical Sciences
Online Access:	http://www.medsci.org/v04p0131.htm

Similar Items

The Human Sodium-Glucose Cotransporter (hSGLT1) Is a Disulfide-Bridged Homodimer with a Re-Entrant C-Terminal Loop.
by: Louis J Sasseville, et al.
Published: (2016-01-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
by: Natalia G. Vallianou, et al.
Published: (2021-06-01)

SGLT2 Inhibitors for Cardioprotection
by: Sulthan Al Rashid, et al.
Published: (2023-07-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs
by: Mutaib M. Mashraqi, et al.
Published: (2021-01-01)

SGLT2 inhibitors: a promising class of antidiabetic agents
by: Camelia DIACONU
Published: (2018-12-01)

SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
by: Chung, YJ, et al.
Published: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

Neuroprotective Effect of SGLT2 Inhibitors
by: Agnieszka Pawlos, et al.
Published: (2021-11-01)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
by: Ewald Kolesnik, et al.
Published: (2022-01-01)

Structural mechanism of SGLT1 inhibitors
by: Yange Niu, et al.
Published: (2022-10-01)

Benefits of SGLT2 inhibitors in arrhythmias
by: Jinghan Gao, et al.
Published: (2022-10-01)

SGLT2 Inhibitor–Induced Sympathoinhibition
by: Lakshini Y. Herat, PhD, et al.
Published: (2020-02-01)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023-06-01)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
by: Victor Chien-Chia Wu, et al.
Published: (2022-09-01)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022-08-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

SGLT2 inhibitors: Beyond glycemic control
by: Irtiza Hasan, et al.
Published: (2024-03-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
by: Carmen Llorens-Cebrià, et al.
Published: (2022-01-01)

SGLT-2 inhibitors and their potential in the treatment of diabetes
by: Rosenwasser RF, et al.
Published: (2013-11-01)

Possible renoprotective mechanisms of SGLT2 inhibitors
by: Akira Nishiyama, et al.
Published: (2023-03-01)

Direct cardiac effects of SGLT2 inhibitors
by: Sha Chen, et al.
Published: (2022-03-01)

Recommendations on the Proper Use of SGLT2 Inhibitors
by: The Committee on the Proper Use of SGLT2 Inhibitors
Published: (2020-01-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
by: Canan Ersoy
Published: (2020-01-01)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
by: José C. De La Flor, et al.
Published: (2023-07-01)

Zaviralci SGLT-2
by: Mojca Lunder, et al.
Published: (2018-10-01)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
by: Aurélie Pahud de Mortanges, et al.
Published: (2021-11-01)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018-02-01)

SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
by: Aritra Paul, et al.
Published: (2024-01-01)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
by: Teresa Salvatore, et al.
Published: (2022-03-01)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023-03-01)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
by: Michail Koutentakis, et al.
Published: (2023-11-01)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
by: Yi-Chou Hou, et al.
Published: (2020-10-01)

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
by: Rajesh Garg, et al.
Published: (2023-10-01)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
by: Jonathan C. H. Chan, et al.
Published: (2023-02-01)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023-05-01)